ArticleCurrent microbiology2025
Antibacterial Potential of BM-MSCs Encapsulated in Collagen-Fibrin Hydrogel for P. anaerobius-Infected Full-Thickness Wounds.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring mesenchymal stem cells as a novel therapeutic approach for HACEK endocarditis: a narrative review.Journal of cardiothoracic surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study investigates the antibacterial potential of murine bone marrow-derived mesenchymal stem cells (BM-MSCs) encapsulated in collagen-fibrin hydrogel scaffolds for treating Peptostreptococcus anaerobius-infected full-thickness wounds. P. anaerobius, a Gram-positive anaerobic coccus, is a significant contributor to wound infections and exhibits considerable antibiotic resistance. Given the rising prevalence of antibiotic-resistant bacteria, there is an urgent need for effective non-antibiotic treatments. One of the non-antibiotic treatments for drug-resistant bacteria is the use of mesenchymal stem cells (MSCs). BM-MSCs were isolated, characterized using CD44, CD90, and CD105 markers, and encapsulated in collagen-fibrin scaffolds. Wound healing progression was monitored over 20 days, and bacterial load reduction was quantified using log CFU/g measurements. Our findings demonstrate a significant reduction in bacterial load (up to 123.33 log CFU/g) and complete wound closure by Day 20, underscoring the dual role of this approach in mitigating microbial infection and promoting wound healing. While scaffold stability and degradation were not directly measured, the observed therapeutic outcomes suggest that the hydrogel remained functional and biocompatible for a sufficient duration to support cell activity and tissue regeneration. These results highlight the innovative potential of BM-MSCs encapsulated in collagen-fibrin hydrogel scaffolds as an effective antibacterial therapy for P. anaerobius-infected wounds.
Indexed as
Identifiers
40820185What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.